Trans Genic Group Inc. · TSE:2342

Trans Genic — Q2 FY2014 Earnings Presentation

46 slides from Trans Genic's earnings presentation, Nov 29, 2013

1. Slide 1: KWWSZZZWUDQVJHQLFFRMS

   ᖹᡂ㻞㻢ᖺ㻟᭶ᮇ➨㻞ᅄ༙ᮇ Ỵ⟬ㄝ᫂఍ 䡚ே䚻䛾೺ᗣ䛸㇏䛛䛺ᬽ䜙䛧䛾䛯䜑䛻䡚 KWWSZZZWUDQVJHQLFFRMS 㻞㻜㻝㻟ᖺ㻝㻝᭶㻞㻥᪥ ᰴᘧ఍♫䝖䝷䞁䝇䝆䜵䝙䝑䜽 ὀ䠖 ᙜ㈨ᩱ䛻グ㍕䛥䜜䛯ෆᐜ䛿䚸⌧᫬Ⅼ䛻䛚䛔䛶୍⯡ⓗ䛻ㄆ㆑䛥䜜䛶䛔䜛⤒῭䞉♫఍➼䛾᝟ໃ䛚䜘䜃ᙜ♫䛜ྜ⌮ⓗ䛸ุ᩿䛧䛯⤒Ⴀィ⏬䛻ᇶ䛵䛝సᡂ 䛧䛶䛚䜚䜎䛩䛜䚸⤒Ⴀ⎔ቃ䛾ኚ໬➼䛾஦⏤䛻䜘䜚䚸ண࿌䛺䛧䛻ኚ᭦䛥䜜䜛ྍ⬟ᛶ䛜䛒䜚䜎䛩䚹䜎䛯䚸௒ᚋ䛾ᙜ♫䛾⤒Ⴀᡂ⦼ཬ䜃㈈ᨻ≧ែ䛻䛴䛝䜎 䛧䛶䛿䚸ᕷሙ䛾ືྥ䚸᪂ᢏ⾡䛾㛤Ⓨཬ䜃➇ྜ௚♫䛾≧ἣ➼䛻䜘䜚䚸኱䛝䛟ኚື䛩䜛ྍ⬟ᛶ䛜䛒䜚䜎䛩䚹

2. Slide 2: Table of Contents

   㼀㼍㼎㼘㼑㻌㼛㼒㻌㻯㼛㼚㼠㼑㼚㼠㼟 ┠ḟ 䊠㻚ᖹᡂ㻞㻢ᖺ㻟᭶ᮇ➨㻞ᅄ༙ᮇ 㐃⤖Ỵ⟬ᴫせ 䊡㻚஦ᴗ䝖䝢䝑䜽䝇 䊢㻚ᖹᡂ㻞㻢ᖺ㻟᭶ᮇ㐃⤖ᴗ⦼ண᝿ 䊣㻚◊✲㛤Ⓨ≧ἣ 䊤㻚◊✲䝖䝢䝑䜽䝇 &RS\ULJKW‹ 7UDQV*HQLF,QF$OO5LJKWV5HVHUYHG

3. Slide 3: Consolidated results overview, Q2 FY March 2014

   䊠㻚ᖹᡂ㻞㻢ᖺ㻟᭶ᮇ ➨㻞ᅄ༙ᮇ㐃⤖Ỵ⟬ᴫせ &RS\ULJKW‹ 7UDQV*HQLF,QF$OO5LJKWV5HVHUYHG

4. Slide 4: Basic Strategies for the Year Ending March 2014

   㻮㼍㼟㼕㼏㻌㻿㼠㼞㼍㼠㼑㼓㼕㼑㼟㻌㼒㼛㼞㻌㼠㼔㼑㻌㼅㼑㼍㼞㻌㻱㼚㼐㼕㼚㼓㻌㻹㼍㼞㼏㼔㻌㻞㻜㻝㻠 ᖹᡂ㻞㻢ᖺ㻟᭶ᮇ ᇶᮏ᪉㔪 䠍䠊䝆䜵䝜䝭䜽䝇஦ᴗ䠄 䠍䠊䝆䜵䝜䝭䜽䝇஦ᴗ䠄㑇ఏᏊ◚ቯ䝬䜴䝇஦ᴗ䚸㑇ఏᏊゎᯒ஦ᴗ䠅 ஦ᴗ䠄㑇ఏᏊ◚ቯ䝬䜴䝇஦ᴗ䚸㑇ఏᏊゎᯒ஦ᴗ䠅 䠄䠍䠅஦ᴗ㒊㛛䛾㯮Ꮠᖜ䜢ᣑ኱ 䠍䠅⏕⏘ຠ⋡໬䛻䜘䜛ᦆ┈ᨵၿ䛾᥎㐍⥅⥆ 䠎䠅᪂つ䝰䝕䝹ື≀䛾཰┈໬ 䠎䠊㻯㻾㻻 䠎䠊㻯㻾㻻஦ᴗ䠄๓⮫ᗋ䞉⮫ᗋヨ㦂 㻯㻾㻻஦ᴗ䠄๓⮫ᗋ䞉⮫ᗋヨ㦂ཷク஦ᴗ䠅 ஦ᴗ䠄๓⮫ᗋ䞉⮫ᗋヨ㦂ཷク஦ᴗ䠅 䠄䠍䠅᪂つᐇ㦂Ჷ䛾✌ാ⋡䛾ᨵၿ 䠄䠎䠅Ꮚ఍♫㻺㻰㻾㻯䛸䛾༠ാ䞉㐃ᦠᙉ໬䛻䜘䜛཰┈ᣑ኱ 䠏䠊ᢠయヨ⸆஦ᴗ䠄 䠏䠊ᢠయヨ⸆஦ᴗ䠄ᢠ

5. Slide 5: Overview of Consolidated Financial Results: Highlights

   㻻㼢㼑㼞㼢㼕㼑㼣㻌㼛㼒㻌㻯㼛㼚㼟㼛㼘㼕㼐㼍㼠㼑㼐㻌㻲㼕㼚㼍㼚㼏㼕㼍㼘㻌㻾㼑㼟㼡㼘㼠㼟 ᖹᡂ㻞㻢ᖺ㻟᭶ᮇ➨㻞ᅄ༙ᮇ㐃⤖Ỵ⟬䠖䝝䜲䝷䜲䝖 䞉䠩䠃䠝ຠᯝ䛻䜘䜚኎ୖ㧗ཬ䜃኎ୖ⥲฼┈኱ᖜቑຍ 䞉䠩䠃䠝ຠᯝ䛻䜘䜚኎ୖ㧗ཬ䜃኎ୖ⥲฼┈኱ᖜቑຍ 䞉ୗᮇ኎ୖ㞟୰ᆺ䛾஦ᴗᣑ኱䛻䜘䜚Ⴀᴗᦆኻ䛿ᚤቑ 䞉䠩䠃䠝㛵㐃㈝⏝䞉㈨㔠ㄪ㐩㈝⏝䛻䜘䜚⤒ᖖᦆኻ䛿ቑຍ ᖹᡂ㻞㻡ᖺ㻟᭶ᮇ ᖹᡂ㻞㻢ᖺ㻟᭶ᮇ ༢఩䠖༓෇ ቑῶ㢠 ቑῶ⋡ ➨䠎ᅄ༙ᮇ ➨䠎ᅄ༙ᮇ ኎ୖ㧗 ኎ୖཎ౯ ኎ୖ⥲฼┈ ㈍⟶㈝ Ⴀᴗᦆኻ 䕦 䕦 䕦 䠉 ⤒ᖖᦆኻ 䕦 䕦 䕦 䠉 ᙜᮇ⣧ᦆኻ 䕦 䕦 䕦 䠉 &RS\ULJKW‹ 7UDQV*HQLF,QF$OO5LJKW

6. Slide 6: Consolidated Results: Net Sales

   㻻㼢㼑㼞㼢㼕㼑㼣㻌㼛㼒㻌㻯㼛㼚㼟㼛㼘㼕㼐㼍㼠㼑㼐㻌㻲㼕㼚㼍㼚㼏㼕㼍㼘㻌㻾㼑㼟㼡㼘㼠㼟 ᖹᡂ㻞㻢ᖺ㻟᭶ᮇ➨㻞ᅄ༙ᮇ㐃⤖Ỵ⟬䠖኎ୖ㧗 ୖᮇ䞉ୗᮇ኎ୖ㧗 㐣ཤ䠏ᮇ㛫䛾᥎⛣ 㐣ཤ䠏ᮇ㛫䛾᥎⛣ 䠄ⓒ୓෇䠅 ᵫᵄᵟјௐỂɥ஖ ୖᮇ ୗᮇ 㻔ண᝿㻕 ‫ݣ‬Э஖ൔᵐᵌᵒ̿Ẇ ᡫ஖ᵐᵌᵕ̿ỉ ٥ɥਘ‫ٻ‬ửʖे + + + &RS\ULJKW‹ 7UDQV*HQLF,QF$OO5LJKWV5HVHUYHG

7. Slide 7: Consolidated Results: Operating Loss

   㻻㼢㼑㼞㼢㼕㼑㼣㻌㼛㼒㻌㻯㼛㼚㼟㼛㼘㼕㼐㼍㼠㼑㼐㻌㻲㼕㼚㼍㼚㼏㼕㼍㼘㻌㻾㼑㼟㼡㼘㼠㼟 ᖹᡂ㻞㻢ᖺ㻟᭶ᮇ➨㻞ᅄ༙ᮇ㐃⤖Ỵ⟬䠖Ⴀᴗᦆ┈ ➨㻞ᅄ༙ᮇႠᴗᦆ┈ 㐣ཤ䠏ᮇ㛫䛾᥎⛣ 㐣ཤ䠏ᮇ㛫䛾᥎⛣ 䠄ⓒ୓෇䠅 ɦ஖͞᣻‫׹‬ʙಅ ୖᮇႠᴗᦆ┈ ୗᮇႠᴗᦆ┈ ỉਘ‫ٻ‬ỆợụẆ ɥ஖փಅ੷ႩỊ 㻔ண᝿㻕 ᘙ᩿ɥफ҄ + + + &RS\ULJKW‹ 7UDQV*HQLF,QF$OO5LJKWV5HVHUYHG

8. Slide 8: Segment Information Summary

   㻻㼢㼑㼞㼢㼕㼑㼣㻌㼛㼒㻌㻯㼛㼚㼟㼛㼘㼕㼐㼍㼠㼑㼐㻌㻲㼕㼚㼍㼚㼏㼕㼍㼘㻌㻾㼑㼟㼡㼘㼠㼟 䝉䜾䝯䞁䝖᝟ሗ䝃䝬䝸䞊 䐟 䠩䠃䠝ຠᯝ䛻䜘䜚඲䝉䜾䝯䞁䝖䛾኎ୖ㧗䛜ቑຍ 䐠 ୗᮇ㞟୰ᆺ䛾䠟䠮䠫஦ᴗつᶍᣑ኱䛻క䛔ୖᮇႠᴗᦆኻᚤቑ ୗᮇ㞟୰ᆺ䛾䠟䠮䠫஦ᴗつᶍᣑ኱䛻క䛔ୖᮇႠᴗᦆኻᚤቑ ᖹᡂ㻞㻡ᖺ㻟᭶ᮇ➨㻞ᅄ༙ᮇ䝉䜾䝯䞁䝖᝟ሗ ༢఩䠖༓෇ 䝆䜵䝜䝭䜽䝇 㻯㻾㻻 ᢠయヨ⸆ ⑓⌮デ᩿ ⟶⌮ 㐃⤖ ኎ୖ㧗 䠉 䠉 Ⴀᴗ㈝⏝ 䠉 Ⴀᴗ฼┈ 䕦 䕦 䠉 䕦 䕦 ᖹᡂ㻞㻢ᖺ㻟᭶ᮇ➨㻞ᅄ༙ᮇ䝉䜾䝯䞁䝖᝟ሗ ༢఩䠖༓෇ 䝆䜵䝜䝭䜽䝇 㻯㻾㻻 ᢠయヨ⸆ ⑓⌮デ᩿ ⟶⌮ 㐃⤖ ኎ୖ㧗 䠉 Ⴀᴗ㈝⏝ Ⴀᴗ฼┈ 䕦 䕦 䕦 &RS\U

9. Slide 9: Segment Results: Genomics Business

   㻻㼢㼑㼞㼢㼕㼑㼣㻌㼛㼒㻌㻿㼍㼘㼑㼟㻌㻾㼑㼢㼑㼚㼡㼑㻌㻙 㻳㼑㼚㼛㼙㼕㼏㼟㻌㻮㼡㼟㼕㼚㼑㼟㼟 䝉䜾䝯䞁䝖ูᴗ⦼ᴫせ䠖䝆䜵䝜䝭䜽䝇஦ᴗ 䝆䜵䝜䝭䜽䝇஦ᴗ 㑇ఏᏊᨵኚ䝬䜴䝇స〇ཷク䛜㡰ㄪ䛻᥎⛣䛧䛯䛣䛸䛻ຍ䛘䚸Ꮚ఍♫໬䛧䛯 䞞䝆䜵䝛䝔䜱䝑䜽䝷䝪䛾㑇ఏᏊゎᯒ஦ᴗ䛜ຍ䜟䜚䚸኱ᖜቑ཰ቑ┈䚹 ➨䠎ᅄ༙ᮇ኎ୖ㧗 ➨䠎ᅄ༙ᮇႠᴗ฼┈ 㻔༓෇㻕 㻔༓෇㻕 + + + + &RS\ULJKW‹ 7UDQV*HQLF,QF$OO5LJKWV5HVHUYHG

10. Slide 10: Segment Results: CRO Business

    㻻㼢㼑㼞㼢㼕㼑㼣㻌㼛㼒㻌㻿㼍㼘㼑㼟㻌㻾㼑㼢㼑㼚㼡㼑㻌㻙㻯㼛㼚㼠㼞㼍㼏㼠㻌㻾㼑㼟㼑㼍㼞㼏㼔㻌㻻㼞㼓㼍㼚㼕㼦㼍㼠㼕㼛㼚㻌㻮㼡㼟㼕㼚㼑㼟㼟 䝉䜾䝯䞁䝖ูᴗ⦼ᴫせ䠖㻯㻾㻻஦ᴗ 㻯㻾㻻஦ᴗ 㻔ᰴ㻕᪂⸆䝸䝃䞊䝏䝉䞁䝍䞊Ꮚ఍♫໬䛻䜘䜛኎ୖ㧗䛾኱ᖜቑຍ䚹 䛺䛚䚸ᦆ┈䛻䛴䛔䛶䛿ୗᮇ೫㔜ᆺ䛾䛯䜑㏫䛻ᝏ໬䛧䚸ቑ཰ῶ┈ ➨䠎ᅄ༙ᮇ኎ୖ㧗 ➨䠎ᅄ༙ᮇႠᴗᦆ┈ 㻔༓෇㻕 㻔༓෇㻕 + + + + &RS\ULJKW‹ 7UDQV*HQLF,QF$OO5LJKWV5HVHUYHG

11. Slide 11: Segment Results: Antibody and Reagent Business

    㻻㼢㼑㼞㼢㼕㼑㼣㻌㼛㼒㻌㻿㼍㼘㼑㼟㻌㻾㼑㼢㼑㼚㼡㼑㻌㻙㻭㼚㼠㼕㼎㼛㼐㼥㻌㼍㼚㼐㻌㻾㼑㼍㼓㼑㼚㼠㻌㻮㼡㼟㼕㼚㼑㼟㼟 䝉䜾䝯䞁䝖ูᴗ⦼ᴫせ䠖ᢠయヨ⸆஦ᴗ ᢠయヨ⸆஦ᴗ 㻔ᰴ㻕䝆䜵䝛䝔䜱䝑䜽䝷䝪Ꮚ఍♫໬䛻䜘䜛ゎᯒ䞉 ᐃ䝃䞊䝡䝇኎ୖቑ䛾⤖ᯝ䚸 ቑ཰ቑ┈䚹 ➨䠎ᅄ༙ᮇ኎ୖ㧗 ➨䠎ᅄ༙ᮇႠᴗ฼┈ 㻔༓෇㻕 㻔༓෇㻕 + + + + &RS\ULJKW‹ 7UDQV*HQLF,QF$OO5LJKWV5HVHUYHG

12. Slide 12: Segment Results: Pathological Diagnostics Business

    㻻㼢㼑㼞㼢㼕㼑㼣㻌㼛㼒㻌㻿㼍㼘㼑㼟㻌㻾㼑㼢㼑㼚㼡㼑㻌㻙㻼㼍㼠㼔㼛㼘㼛㼓㼕㼏㼍㼘㻌㻰㼕㼍㼓㼚㼛㼟㼠㼕㼏㼟 㻮㼡㼟㼕㼚㼑㼟㼟 䝉䜾䝯䞁䝖ูᴗ⦼ᴫせ䠖⑓⌮デ᩿஦ᴗ ⑓⌮デ᩿஦ᴗ ᙜ➨ᅄ༙ᮇ㐃⤖఍ィᮇ㛫䜘䜚䚸 ᰴ 䝆䜵䝛䝔䝑䜽䝷䝪䛾⑓⌮デ᩿䝃䞊䝡䝇䛜 ᪂つ஦ᴗ䛸䛧䛶㏣ຍ䚹 ➨䠎ᅄ༙ᮇ኎ୖ㧗 ➨䠎ᅄ༙ᮇႠᴗ฼┈ 㻔༓෇㻕 㻔༓෇㻕 + + + + &RS\ULJKW‹ 7UDQV*HQLF,QF$OO5LJKWV5HVHUYHG

13. Slide 13: Segment Net Sales Trend

    㻻㼢㼑㼞㼢㼕㼑㼣㻌㼛㼒㻌㻯㼛㼚㼟㼛㼘㼕㼐㼍㼠㼑㼐㻌㻲㼕㼚㼍㼚㼏㼕㼍㼘㻌㻾㼑㼟㼡㼘㼠㼟 䝉䜾䝯䞁䝖ูᴗ⦼ᴫせ䠖኎ୖ㧗᥎⛣ 䠄ண᝿䠅 ண᝿䠅 䝉䜾䝯䞁䝖ู኎ୖ㧗 䝉䜾䝯䞁䝖ู኎ୖ㧗 㐣ཤ䠏ᮇ㛫䛾᥎⛣ 㐣ཤ䠏ᮇ㛫䛾᥎⛣ 䝆䜵䝜䝭䜽䝇஦ᴗ ᢠయヨ⸆஦ᴗ ᵫᵄᵟỆợỦμ˳ &52஦ᴗ䠄ྵ 1'5& ⑓⌮デ᩿஦ᴗ 䈜⑓⌮デ᩿䛿㻴㻞㻢㻚㻤䜘䜚㛤ጞ ٥ɥὉμἍἂἳὅἚ ٥ɥỉਘ‫ٻ‬ 䠄ⓒ୓෇䠅 ୖᮇ ୗᮇ ୖᮇ ୗᮇ ୖᮇ ୗᮇ + + + &RS\ULJKW‹ 7UDQV*HQLF,QF$OO5LJKWV5HVHUYHG

14. Slide 14: Segment Operating Profit/Loss Trend

    㻻㼢㼑㼞㼢㼕㼑㼣㻌㼛㼒㻌㻯㼛㼚㼟㼛㼘㼕㼐㼍㼠㼑㼐㻌㻲㼕㼚㼍㼚㼏㼕㼍㼘㻌㻾㼑㼟㼡㼘㼠㼟 䝉䜾䝯䞁䝖ูᴗ⦼ᴫせ䠖Ⴀᴗᦆ┈᥎⛣ 䝉䜾䝯䞁䝖ูႠᴗᦆ┈ 䝉䜾䝯䞁䝖ูႠᴗᦆ┈ 㐣ཤ䠏ᮇ㛫䛾᥎⛣ 㐣ཤ䠏ᮇ㛫䛾᥎⛣ ண᝿䠅 ண᝿䠅 䝆䜵䝜䝭䜽䝇஦ᴗ &52஦ᴗ䠄ྵ 1'5& ᢠయヨ⸆஦ᴗ ⑓⌮デ᩿஦ᴗ μ˳٥ɥὉμἍἂἳ 䈜⑓⌮デ᩿䛿㻴㻞㻢㻚㻤䜘䜚㛤ጞ ὅἚ٥ɥỉਘ‫ٻ‬Ệˤ 䠄ⓒ୓෇䠅 ẟɦ஖փಅМႩờ ਘ‫ٻ‬ ୖᮇ ୗᮇ ୖᮇ ୗᮇ ୖᮇ ୗᮇ + + + &RS\ULJKW‹ 7UDQV*HQLF,QF$OO5LJKWV5HVHUYHG

15. Slide 15: Consolidated Results: Ordinary Loss

    㻻㼢㼑㼞㼢㼕㼑㼣㻌㼛㼒㻌㻯㼛㼚㼟㼛㼘㼕㼐㼍㼠㼑㼐㻌㻲㼕㼚㼍㼚㼏㼕㼍㼘㻌㻾㼑㼟㼡㼘㼠㼟 ᖹᡂ㻞㻢ᖺ㻟᭶ᮇ➨㻞ᅄ༙ᮇ㐃⤖Ỵ⟬䠖⤒ᖖᦆ┈ ➨䠎ᅄ༙ᮇ⤒ᖖᦆ┈ ༙ᮇ⤒ᖖᦆ┈ ᵫᵄᵟᝲဇίᵏᵐႊɢόὸ 䠄ⓒ୓෇䠅 + + ӏỎ᝻᣿ᛦᢋ᧙ᡲ ᝲဇίᵏᵗႊɢόὸỉ ᝟ਃỆợụɥ஖ኺࠝ ੷‫ڂ‬Ịਘ‫ٻ‬ &RS\ULJKW‹ 7UDQV*HQLF,QF$OO5LJKWV5HVHUYHG

16. Slide 16: Consolidated Results: Net Loss

    㻻㼢㼑㼞㼢㼕㼑㼣㻌㼛㼒㻌㻯㼛㼚㼟㼛㼘㼕㼐㼍㼠㼑㼐㻌㻲㼕㼚㼍㼚㼏㼕㼍㼘㻌㻾㼑㼟㼡㼘㼠㼟 ᖹᡂ㻞㻢ᖺ㻟᭶ᮇ➨㻞ᅄ༙ᮇ㐃⤖Ỵ⟬䠖ᙜᮇ⣧ᦆ┈ ➨䠎ᅄ༙ᮇ⣧ᦆ┈ ኺࠝ੷‫ࠢڂ‬ỉਘ‫ٻ‬ 䠄ⓒ୓෇䠅 + + ӏỎ৲᝻ఇࡸỉ ᚸ̖੷ίᵕႊɢόὸ Ệợụɥ஖ ኝ੷‫ࠢڂ‬ờਘ‫ٻ‬ &RS\ULJKW‹ 7UDQV*HQLF,QF$OO5LJKWV5HVHUYHG

17. Slide 17: Business Topics

    䊡㻚஦ᴗ䝖䝢䝑䜽䝇 &RS\ULJKW‹ 7UDQV*HQLF,QF$OO5LJKWV5HVHUYHG

18. Slide 18: TransGenic Group Structure Chart

    㻻㼢㼑㼞㼢㼕㼑㼣㻌㼛㼒㻌㼀㼞㼍㼚㼟㻳㼑㼚㼕㼏 㻳㼞㼛㼡㼜㼟 䝖䝷䞁䝇䝆䜵䝙䝑䜽䜾䝹䞊䝥ᴫせ䠖䜾䝹䞊䝥ᵓᡂᅗ 䠄㻞㻜㻝㻟ᖺ㻣᭶㻟㻝᪥⌧ᅾ䠅 ४ख़ঀ঑ॡ५ &52 ಿ৬૥ఇ হ঵ম৖ হ঵ম৖ হ঵ম৖ ‫ٳ‬఩஫৕੝૗ঐक़५੿ଲ ‫ٳ‬శಏ෫૥ୡ‫ق‬প৿੟‫ك‬ ‫ٳ‬ӗӍҼӟҴӉӝಿ৬੿ଲ ‫ٳ‬఩஫৕৅ਠੰෲ ‫ٳ‬ӄӡӎӣҼସৈ৅ਠ಍ཝ੿ଲ ‫ٳ‬ӎӢҶҹӓҴҺҴ৫৅ ৴੥৕ভ঺ ੅ী১ి৷ ঢ়৴ভ঺ &52হ঵ 602হ঵ ୰৶൧૵হ঵ ଢ଼஢৷૥ఇহ঵ ಿ৬হ঵ ઙૄভ঺ ઙૄভ঺ ઙૄভ঺ ઙૄভ঺ ઙૄভ঺ ৗఇজ१‫ॳش‬७থॱ‫ش‬ ওॹॕইज़঒ ४ख़ॿॸॕॵॡছ঎ উছॖ঑গ

19. Slide 19: TransGenic Groups: Area Map

    㻻㼢㼑㼞㼢㼕㼑㼣㻌㼛㼒㻌㼀㼞㼍㼚㼟㻳㼑㼚㼕㼏 㻳㼞㼛㼡㼜㼟 䝖䝷䞁䝇䝆䜵䝙䝑䜽䜾䝹䞊䝥ᴫせ䠖䜶䝸䜰䝬䝑䝥 ਝ য় ফা ਝ য় ফা ਝ য় ফা జ঵৩ਯ ੡‫౐ق‬৬‫ك‬ జ঵৩ਯ ੡ జ঵৩ਯ ੡ হ঵ਚ হ঵ਚ হ঵ਚ ম঺ ിম৘রఙયృષ஁ഛ৯୞ಀ ম঺ ূ਎੃௃યႊঀ୅ഛ৯୞ಀ ম঺ ਨਲ੊౩൦৘ૺ༺୞৉ ઋૺଢ଼஢ਚ ઋૺ৘রఙય௃ਣવ঴ഛ৯୞৉ রఙଢ଼஢ਚ ਨਲ੊౩൦৘ૺ༺୞৉ ূ਎হਜਚ ূ਎੃௃યႊঀ୅ഛ৯୞ಀ ਝ য় ফা జ঵৩ਯ ੡ হ঵ਚ ਝ য় ফা ম঺ ైච৘রఙયਨ૖ਧഛ৯୞৉ ম ঺ ઋૺ৘রఙય௃ਣવ঴ഛ৯୞৉ ূ਎হਜਚ ূ਎੃௃યႊঀ୅ഛ৯୞ಀ &

20. Slide 20: Total Support Business

    㻻㼢㼑㼞㼢㼕㼑㼣㻌㼛㼒㻌㼀㼞㼍㼚㼟㻳㼑㼚㼕㼏 㻳㼞㼛㼡㼜㼟 䝖䝷䞁䝇䝆䜵䝙䝑䜽䜾䝹䞊䝥ᴫせ䠖䝖䞊䝍䝹䝃䝫䞊䝖஦ᴗ ᇶ♏◊✲䚸㠀⮫ᗋヨ㦂䚸⮫ᗋヨ㦂デ᩿䜎䛷䛾䝅䞊䝮䝺䝇䛺䝃䝫䞊䝖䜢䛤ᥦ౪ ർด੦ຊଢ଼஢ ৵৿੟पेॊ প৿੟पेॊ ಏ෫૥ୡ ൧૵ ൉ఇଢ଼஢ శಏ෫૥ୡ శಏ෫૥ୡ ઙૄভ঺ ઙૄভ঺ ઙૄভ঺ ઙૄভ঺ ઙૄভ঺ ॺছথ५४ख़ॽॵॡ ৗఇজ१‫ॳش‬७থॱ‫ش‬ ॺছথ५४ख़ॽॵॡ ৗఇজ१‫ॳش‬७থॱ‫ش‬ ४ख़ॿॸॕॵॡছ঎ ఩஫৕੝૗ঐक़५੿ଲ ୢఇષ‫ؚ‬୫ષ‫ؚ‬৲ဲષ‫ؚ‬ ਍৸ਙ‫્ؚ‬໰ఇ৶૥ୡಉ ে੟৾৓৊ಉਙ૥ୡಉभ ੌ୰৶ੌ௶൧૵ ఩஫৕৅ਠੰෲ ৲৾੟ସಉभ

21. Slide 21: Business Overview: Contract Research

    㻻㼢㼑㼞㼢㼕㼑㼣㻌㼛㼒㻌㼀㼞㼍㼚㼟㻳㼑㼚㼕㼏 㻳㼞㼛㼡㼜㼟 ⌆ॺছথ५४ख़ॽॵॡ ᥈⣴ᇶ♏◊✲ ᑠື≀䛻䜘䜛 ኱ື≀䛻䜘䜛 ⮫ᗋヨ㦂 デ᩿ ๰⸆◊✲ 㠀⮫ᗋヨ㦂 㠀⮫ᗋヨ㦂 ‫؞‬੔ഈૼ୒॑৳થघॊ఩஫৕੝૗ঐक़५भঃॖड़ॽ॔ ४ख़ঀ঑ॡ५ ಿ৬૥ఇ হ঵ম৖ হ঵ম৖ ‫؞‬7*ঐक़५॑৷ःञৈ஡ਮਙಿ৬भ੿ଲ ઀୹१‫ش‬অ५ ْ఩஫৕੝૗ঐक़५੿ଲਭ౏ٓ ْಿ৬‫ॱ؞‬থঃॡঢ়৴ਭ౏ٓ 9 ॥থঋথ३ঙॼঝ.2ঐक़५੿ଲ 9 *$13œৈ஡ਮਙಿ৬੿ଲ 9 ॥থॹॕ३ঙॼঝ.2ঐक़५੿ଲ 9 ঔঀॡট‫ॼش‬ঝಿ৬੿ଲ 9 ঀॵॡॖথঐक़५੿ଲ 9 ॱথঃॡସৈ৅ਠ಍ཝ੿ଲ 9 ॺছথ५

22. Slide 22: Business Overview: Antibody Reagents

    㻻㼢㼑㼞㼢㼕㼑㼣㻌㼛㼒㻌㼀㼞㼍㼚㼟㻳㼑㼚㼕㼏 㻳㼞㼛㼡㼜㼟 ⌆ৗఇজ१‫ॳش‬७থॱ‫ش‬ ᥈⣴ᇶ♏◊✲ ᑠື≀䛻䜘䜛 ኱ື≀䛻䜘䜛 ⮫ᗋヨ㦂 デ᩿ ๰⸆◊✲ 㠀⮫ᗋヨ㦂 㠀⮫ᗋヨ㦂 ‫؞‬ফभഄఴपഫહऐऔोञਦ౅धৰౚ ‫*؞‬/3઱ਝद໮஋औोञૼ୒‫؞‬१‫ش‬অ५ 9 ႇႌ୰ঔॹঝ ઀୹१‫ش‬অ५ 9 ৰୡ৓পႯ༇ঔॹঝ ਍৸ਙ૥ୡ ْႲਃચٓ ْୢఇષ਍৸ਙ૥ୡٓ 9 Ⴒඪঔॹঝ ‫ق‬ӓҷӁ‫ؚ‬ӛҳӈ‫ؚ‬ҷҿһӢ‫ؚ‬ӗӝӗҳӈ‫ك‬ ْඊႵ‫ؚ॔‬ঞঝॠ‫ش‬ঢ়৴ٓ 9 ᶾᶪਃચঔॹঝ ْୢ௜ਃஓ਍৸ਙ૥ୡٓ 9 ঽேඊႵ௺ ‫ق‬ӛҳӈ‫ؚ‬ҷҿһӢ‫ك‬ 9 ႯଵඊႵ

23. Slide 23: Business Overview: CRO

    㻻㼢㼑㼞㼢㼕㼑㼣㻌㼛㼒㻌㼀㼞㼍㼚㼟㻳㼑㼚㼕㼏 㻳㼞㼛㼡㼜㼟 ⌆ॺছথ५४ख़ॽॵॡ ᥈⣴ᇶ♏◊✲ ᑠື≀䛻䜘䜛 ኱ື≀䛻䜘䜛 ⮫ᗋヨ㦂 デ᩿ ๰⸆◊✲ 㠀⮫ᗋヨ㦂 㠀⮫ᗋヨ㦂 ‫؞‬ব৔दुથਯभૼ୒‫৽؞‬ୡ௹୕ऩ ‫؞‬ঽ঺઱ਝ‫ق‬ઋૺএ‫॔ش‬ॖ‫ك‬ध &52 ৰୡॳ‫ش‬঒ऋ૔ආ হ঵ম৖ ব৔ਗঞথॱঝছ঎॑ણ৷ ઀୹१‫ش‬অ५ ْ༇ඪ‫؞‬倻൱ٓ 9 ॥ছ‫ش‬।থঢ়ත༇ঔॹঝ 9 ॽগ‫ش‬টঃ३ॵॡঌॖথঔॹঝ ْরᆏઋ৽௺ٓ 9 ঃ‫ش‬य़থ९থ୰ঔॹঝ ْ࿯୭ஓ௺ٓ 9 ౼ዄኋঔॹঝ 9 ੱ൙ዄኋঔॹঝ ‫૶ ص‬ਙ‫ ؚ‬ཿਙ‫༘ ؚ‬ഷગ৫ৢ‫ص‬ 9 ੱ൙ዄኋગ৫

24. Slide 24: Business Overview: Antibody Reagents and Pathology

    㻻㼢㼑㼞㼢㼕㼑㼣㻌㼛㼒㻌㼀㼞㼍㼚㼟㻳㼑㼚㼕㼏 㻳㼞㼛㼡㼜㼟 ⌆ৗఇজ१‫ॳش‬७থॱ‫ش‬ ⌆ওॹॕইज़঒ ᥈⣴ᇶ♏◊✲ ᑠື≀䛻䜘䜛 ኱ື≀䛻䜘䜛 ⮫ᗋヨ㦂 デ᩿ ๰⸆◊✲ 㠀⮫ᗋヨ㦂 㠀⮫ᗋヨ㦂 ૥ୡ੻౏੫঵੍ର *&3‫؞‬ঊঝ३থय़്੉ ૆ು ୢ௜ਃঢ়੍ର ઀୹१‫ش‬অ५ ୢఇಏ෫૥ୡ ْਭ౏૥ୡٓ ْਭ౏঵ਜٓ 9 ে੟৾৓৊ಉਙ૥ୡ 9 ੘ୡிભୢప఺लৰ઱ୢ௜ਃঢ়भ৭ 9 ఇ੟৿ଙ૥ୡ ৒प૑ਏऩੲਾभઽૐ఺ल઀୹ 9 ଂਚຜჹి৷ଲදभ৊ಉਙ૥ୡ 9 ੘ୡৰ઱ੑ઺છ੧‫؜‬ඪ୻ਾઔછ੧ಉ 9 ຜჹ਍৸ਙ૥ୡ‫ق‬ঃॵॳॸ५ॺ‫ك‬ भધછ੿ਛ੍ର ୫ષಏ෫૥ୡ 9 ୢ৾௧୅ੇ

25. Slide 25: Business Overview: Pathological Diagnostics

    㻻㼢㼑㼞㼢㼕㼑㼣㻌㼛㼒㻌㼀㼞㼍㼚㼟㻳㼑㼚㼕㼏 㻳㼞㼛㼡㼜㼟 ᥈⣴ᇶ♏◊✲ ᑠື≀䛻䜘䜛 ኱ື≀䛻䜘䜛 ๰⸆◊✲ 㠀⮫ᗋヨ㦂 㠀⮫ᗋヨ㦂 ⮫ᗋヨ㦂 デ᩿ ‫௶ੌ؞‬୰৶৾৓ু১ध఩஫৕ੰෲૼ୒भৈઃ੪ऩ੆় ‫଻؞‬શ৲ୢ௜୸ਛभञी‫ؚ‬ਉ౫મ৹ଲऊै૥ୡ১ଡണऽद॑ইঝ१এ‫ॺش‬ ઀୹१‫ش‬অ५ 9 ੌ௶॔ঞॖ੿ଲ‫ق‬7LVVXH0LFUR$UUD\‫ك‬ 9 ્໰ഉ౦ ‫؝ڭ‬୰৶൧૵१‫ش‬অ५ 9 ዓ୾LQVLWXK\EULGL]DWLRQ ),6+ 9 ୰৶ੌ௶൧૵ 9 ඊႵੌ௶৲৾‫ق‬ዓ୾‫ك‬ഉ౦‫ق‬,+&‫ك‬ 9 ಍ཝ൧૵ 9 ),6+,+&भഉ౦ਘ২भ৒୤௬੼ 9

26. Slide 26: Consolidated Forecast, FY March 2014

    䊢㻚ᖹᡂ㻞㻢ᖺ㻟᭶ᮇ㐃⤖ᴗ⦼ண᝿ &RS\ULJKW‹ 7UDQV*HQLF,QF$OO5LJKWV5HVHUYHG

27. Slide 27: Consolidated Business Forecast for Year Ending March 2014

    㻯㼛㼚㼟㼛㼘㼕㼐㼍㼠㼑㼐㻌㻮㼡㼟㼕㼚㼑㼟㼟㻌㻲㼛㼞㼑㼏㼍㼟㼠㻌㼒㼛㼞㻌㼠㼔㼑㻌㼅㼑㼍㼞㻌㻱㼚㼐㼕㼚㼓㻌㻹㼍㼞㼏㼔㻌㻞㻜㻝㻠 ᖹᡂ㻞㻢ᖺ㻟᭶ᮇ 㐃⤖ᴗ⦼ண᝿ ୗᮇ䛻኎ୖ䛜㞟୰䛩䜛䠟䠮䠫஦ᴗཬ䜃㻤 ୗᮇ䛻኎ୖ䛜㞟୰䛩䜛䠟䠮䠫஦ᴗཬ䜃㻤᭶䛛䜙䜾䝹䞊䝥䛻ຍ䜟䛳䛯 䝆䜵䝛䝔䜱䝑䜽䝷䝪䛾ᴗ⦼ຠᯝ䛻䜘䜚䚸ୗᮇ䛿኱ᖜቑ཰䞉ቑ┈䜢ண᝿ ᖹᡂ㻞㻢 ᖹᡂ㻞㻢ᖺ 㻞㻢ᖺ㻟᭶ᮇ ᖹᡂ㻞㻢 ᖹᡂ㻞㻢ᖺ 㻞㻢ᖺ㻟᭶ᮇ ᖹᡂ㻞㻢 ᖹᡂ㻞㻢ᖺ 㻞㻢ᖺ㻟᭶ᮇ ༢఩䠖༓෇ ➨㻞ᅄ༙ᮇ⣼ィ ୗᮇ ㏻ᮇ 䠄ᐇ⦼䠅 䠄ண᝿䠅 䠄ண᝿䠅 ኎ୖ㧗 䝆䜵䝜䝭䜽䝇஦ᴗ 㻯㻾㻻஦ᴗ 㻯㻾㻻஦ᴗ ᢠయヨ⸆஦ᴗ ⑓⌮デ᩿஦ᴗ Ⴀᴗ㈝⏝ Ⴀᴗ฼┈ 䕦

28. Slide 28: Research and Development Status

    䊣㻚◊✲㛤Ⓨ≧ἣ &RS\ULJKW‹ 7UDQV*HQLF,QF$OO5LJKWV5HVHUYHG

29. Slide 29: Topics of Research & Development

    㼀㼛㼜㼕㼏㼟㻌㼛㼒㻌㻾㼑㼟㼑㼍㼞㼏㼔㻌㻒㻌㻰㼑㼢㼑㼘㼛㼜㼙㼑㼚㼠 ᖹᡂ㻞㻡ᖺ ◊✲㛤Ⓨ䝖䝢䝑䜽䝇 㻞᭶ ᙜ♫⊂⮬ᢏ⾡䛾ྍኚᆺ䝖䝷䝑䝥ἲᢏ⾡䜢⏝䛔䛯◊✲ᡂᯝ䛜䛂㻼㻸㻻㻿㻌㻳㻱㻺㻱㼀㻵㻯㻿䛃䛻ᥖ㍕ 䠐᭶ 䛂䝖䝷䝑䝥䝬䜴䝇ᢏ⾡䛃䛻㛵䛩䜛≉チ䛜୰ᅜ䛻䛶ᡂ❧ 䛂䝖䝷䝑䝥䝬䜴䝇ᢏ⾡䛃䛻㛵䛩䜛≉チ䛜୰ᅜ䛻䛶ᡂ❧ 㻡᭶ 䝯䝍䝪䝸䝑䜽䝅䞁䝗䝻䞊䝮䝬䞊䜹䞊䛻㛵䛩䜛◊✲ᡂᯝ䛜䛂㻯㼑㼘㼘㻌㻾㼑㼜㼛㼞㼠㼟䛃䛻ᥖ㍕ 㻳㻭㻺㻼㼹䝬䜴䝇ᢏ⾡䛻㛵䛩䜛◊✲ᡂᯝ䛜䛂㻺㼍㼠㼡㼞㼑㻌㻯㼛㼙㼙㼡㼚㼕㼏㼍㼠㼕㼛㼚㼟䛃䛻ᥖ㍕ 䛄⑓ែྍど໬䝬䜴䝇䛅䛾䝟䝣䜷䞊䝬䞁䝇䜢᭦䛻ྥୖ䛥䛫䛶ᥦ౪㛤ጞ 䛄㻾㼛㼟㼍㻞㻢㑇ఏᏊ䜢⏝䛔䛯㻷㼚㼛㼏㼗㻙㼕㼚䝬䜴䝇䛅స

30. Slide 30: Our Intellectual Property: Patent Status

    㻻㼡㼞㻌㻵㼚㼠㼑㼘㼘㼑㼏㼠㼡㼍㼘㻌㻼㼞㼛㼜㼑㼞㼠㼥 ୺せ䛺≉チ䛾ᡂ❧≧ἣ 䝖䝷䝑䝥䝬䜴䝇ᢏ⾡ 䛄$8䛅䛅 䜸䞊䝇䝖䝷䝸䜰䛻䛶ᡂ❧ 㻞㻜㻜㻡ᖺ 㻞㻜㻜㻡ᖺ㻠᭶ 䛄86䛅 䛅 ⡿ᅜ䛻䛶ᡂ❧ 㻞㻜㻜㻣ᖺ 㻞㻜㻜㻣ᖺ㻝㻞᭶ 㻝㻞᭶ 䛄(3䛅䛅 Ḣᕞ䛻䛶ᡂ❧ 㻞㻜㻝㻜ᖺ 㻞㻜㻝㻜ᖺ㻟᭶ 䛄=/䛅䛅 ୰ᅜ䛻䛶ᡂ❧ 㻞㻜㻝㻜ᖺ 㻞㻜㻝㻜ᖺ㻢᭶ 䛄+.%䛅 䛅 㤶 䛻䛶ᡂ❧ 㻞㻜㻝㻜ᖺ 㻞㻜㻝㻜ᖺ㻝㻞᭶ 㻝㻞᭶ 䛄-3䛅䛅 ᪥ᮏ䛻䛶ᡂ❧ ᪥ᮏ䛻䛶ᡂ❧ 㻞㻜㻝㻝ᖺ 㻞㻜㻝㻝ᖺ㻞᭶ 䛄=/䛅 䛅୰ᅜ䛻䛶ᡂ❧ 㻞㻜㻝㻟ᖺ 㻞㻜㻝㻟ᖺ㻠᭶ 䠣䠝䠪䠬Š䝬䜴䝇ᢏ⾡ 䠣䠝䠪䠬 䝬䜴䝇ᢏ⾡ 䛄=/䛅 䛅୰ᅜ䛻䛶ᡂ❧ 㻞㻜㻜㻤

31. Slide 31: Overview of Research & Development Pipeline

    㻻㼢㼑㼞㼢㼕㼑㼣㻌㼛㼒㻌㻾㼑㼟㼑㼍㼞㼏㼔㻌㻒㻌㻰㼑㼢㼑㼘㼛㼜㼙㼑㼚㼠㻌㻼㼕㼜㼑㼘㼕㼚㼑 㛤Ⓨ䝟䜲䝥䝷䜲䞁≧ἣ ⣙㻟ᖺ ⣙㻞ᖺ 䝷䜲䝉䞁䝇 䝍䞊䝀䝑䝖 ᢠయ ᭷⏝ᛶ ᐃ⣔ 䜰䜴䝖 ୖᕷ ྠᐃ స〇 ᳨ド ᵓ⠏ ⮫ᗋ㛤Ⓨ ▷ ᢠయ〇ရ䛾㛤Ⓨ እ㒊◊✲ᶵ㛵䛛䜙䛾ᑟධ㛤Ⓨ ᮇ ୖᕷ䛻ྥ䛡㐍⾜୰ ᒀ୰䛜䜣䝬䞊䜹䞊 ஑ᕞ኱Ꮫ➼ 㻔デ᩿⸆䝯䞊䜹䞊䠅 䈜୰ᅜ௻ᴗ䜈䝷䜲䝉䞁䝇ዎ⣙ ᅜ❧ 䝷䜲䝉䞁䝇ඛ஺΅୰ ⮅䛜䜣䝬䞊䜹䞊 䛜䜣䝉䞁䝍䞊 ㏣ຍ䝕䞊䝍⵳✚୰ ㏣ຍ䝕䞊䝍⵳✚୰ 䈜䠄ᰴ䠅ච␿⏕≀◊✲ᡤ䛸ඹྠ◊✲ 䈜୰ᅜ௻ᴗ䛸㻲㻿 ୰ᅜ௻ᴗ䛸㻲㻿ዎ⣙ 㻲㻿ዎ⣙ ᐃ䜻䝑䝖㈍኎୰ ᐃ䜻䝑䝖㈍኎୰ Ἢᒀჾ䛜䜣䝬䞊䜹䞊 㡰ኳᇽ኱

32. Slide 32: Technical Expertise: Features of Trap Vector

    㼀㼑㼏㼔㼚㼕㼏㼍㼘㻌㻱㼤㼜㼑㼞㼠㼕㼟㼑 䝖䝷䝑䝥䝧䜽䝍䞊䛂㼜㼁㻝㻣䛃䛾≉ᚩ 7*$ OR[ $7* OR[3 OR[ OR[ 6$ EJHR S$ S63 䛺䛬䝥䝻䝰䞊䝍䞊䝖䝷䝑䝥䛻䛺䜛䛾䛛 ୖグ䛾ᵓ㐀䜢ᣢ䛴䝧䜽䝍䞊䛜䚸䝬䜴䝇㑇ఏᏊ䛾ୗὶ䛻⤌㎸䜎䜜䛯ሙྜ䛿䚸 䠍䠊ୖὶ䛛䜙⩻ヂ䛥䜜䛯䝍䞁䝟䜽䛿䚸䝧䜽䝍䞊ෆ䛾೵Ṇ䝁䝗䞁䛷⤊⤖䛩䜛䚹䛧䛯 䛜䛳䛶䚸EJHR䛿Ⓨ⌧䛫䛪䚸䝛䜸⪏ᛶ䛸䛺䜙䛺䛔䚹䛴䜎䜚䚸䝛䜸䝬䜲䝅䞁Ꮡᅾ 䛜䛳䛶䚸E 䛿Ⓨ⌧䛫䛪䚸䝛䜸⪏ᛶ䛸䛺䜙䛺䛔䚹䛴䜎䜚䚸䝛䜸䝬䜲䝅䞁Ꮡᅾ ୗ䛷䛿䛣䛾䜘䛖䛺(6⣽⬊䛿Ṛ⁛䛩䜛䚹 ୗ䛷䛿䛣䛾䜘䛖䛺 ⣽⬊䛿Ṛ⁛䛩䜛䚹 䠎䠊EJHR䛜⩻ヂ䛥䜜䜛䛯䜑䛻䛿䚸 䠎䠊E 䛜⩻

33. Slide 33: Features of Conditional Gene Trap Method

    㼀㼑㼏㼔㼚㼕㼏㼍㼘㻌㻱㼤㼜㼑㼞㼠㼕㼟㼑 ྍኚᆺ㑇ఏᏊ䝖䝷䝑䝥ἲ䛾≉ᚩ 䠍䠊㑇ఏᏊ䝖䝷䝑䝥䛾䛖䛱䛾䝥䝻䝰䞊䝍䝖䝷䝑䝥 䖾䝬䜴䝇㑇ఏᏊ䜢䜋䜌᏶඲◚ቯ 䠎䠊䝧䜽䝍䞊䛾୰䛻E㻙㼓㼑㼛㑇ఏᏊ䛜ᤄධ䛥䜜䛶䛔䜛 䖾Ⓨ⌧䝟䝍䞊䞁䛾ゎᯒ䛜ᐜ᫆䠖㼄㻙㼓㼍㼘ᰁⰍ䛷ྍ⬟ 䠏䠊㑇ఏᏊ◚ቯ䝬䜴䝇䛾స〇䛸ゎᯒ 䖾⾲⌧ᆺゎᯒ䛛䜙䚸㑇ఏᏊᶵ⬟䛾ྠᐃ 䠐䠊㼘㼛㼤㻣㻝㻙㼘㼛㼤㻼䜹䝉䝑䝖䛜⤌㎸䜎䜜䛶䛔䜛 䖾㑇ఏᏊ⨨᥮䛜ྍ⬟ 䠑䠊┦ྠ⤌᥮䛘䝧䜽䝍䞊䛻䜒ᛂ⏝ྍ⬟ 䖾ྍኚᆺ┦ྠ⤌᥮䛘ἲ &RS\ULJKW‹ 7UDQV*HQLF,QF$OO5LJKWV5HVHUYHG

34. Slide 34: Technical Expertise: Example Lgr4

    㼀㼑㼏㼔㼚㼕㼏㼍㼘㻌㻱㼤㼜㼑㼞㼠㼕㼟㼑 ౛㻦㻌㻸㼓㼞㻠㻌㻔㻴㼛㼟㼔㼕㼕 㼑㼠㻌㼍㼘㻚㻌㻮㼕㼛㼘㻚㻌 㼑㼠㻌㼍㼘㻚㻌㻮㼕㼛㼘㻚㻌㻾㼑㼜㼞㼛㼐 㻮㼕㼛㼘㻚㻌㻾㼑㼜㼞㼛㼐㻚㻌㻣㻢㻦㻟㻜㻟 㻾㼑㼜㼞㼛㼐㻚㻌㻣㻢㻦㻟㻜㻟㻙 㻚㻌㻣㻢㻦㻟㻜㻟㻙㻟㻝㻟㻘㻌㻞㻜㻜㻣㻕 㻟㻝㻟㻘㻌㻞㻜㻜㻣㻕 $7* ([RQa 7*$ 㻞 䝜䝄䞁䝤䝻䝑䝖 ⢭ᕢୖయ䛾పᙧᡂ ⬻ ⫶ ⭈ ,QLWLDOVHJPHQW䛾Ḟᦆ 䛾Ḟᦆ *W *W*W *W *W*W *W *W*W *W *W*W &D &D ,6 (' (' &R &R ;JDOᰁⰍ ᰁⰍ GSF GSS GSS DQWLP(3DQWLERG\ &R('(IIHUH

35. Slide 35: Technical Expertise: Example Abhd2

    㼀㼑㼏㼔㼚㼕㼏㼍㼘㻌㻱㼤㼜㼑㼞㼠㼕㼟㼑 ౛㻦㻌㻭㼎㼔㼐㻞㻌㻔㻹㼕㼥㼍㼠㼍㻌㼑㼠㻌㼍㼘㻚㻌㻮㼕㼛㼏㼔㼑㼙 㻔㻹㼕㼥㼍㼠㼍㻌㼑㼠㻌㼍㼘㻚㻌㻮㼕㼛㼏㼔㼑㼙㻚㻌 㻮㼕㼛㼏㼔㼑㼙㻚㻌㻮㼕㼛㼜㼔㼥㼟 㻚㻌㻮㼕㼛㼜㼔㼥㼟㻚㻌㻾㼑㼟㻚㻌 㻮㼕㼛㼜㼔㼥㼟㻚㻌㻾㼑㼟㻚㻌㻯㼛㼙㼙㼡㼚 㻚㻌㻾㼑㼟㻚㻌㻯㼛㼙㼙㼡㼚㻚㻌㻟㻢㻡 㻯㼛㼙㼙㼡㼚㻚㻌㻟㻢㻡㻦㻞㻜㻣 㻚㻌㻟㻢㻡㻦㻞㻜㻣㻙 㻦㻞㻜㻣㻙㻞㻝㻟㻘㻌㻞㻜㻜㻤㻚㻕 㻞㻝㻟㻘㻌㻞㻜㻜㻤㻚㻕 $7* 7*$ ;JDOVWDLQLQJ 䝜䝄䞁䝤䝻䝑䝖 $EKG*W $EKG*W*W %U +H /X /L %U +H /X /L %U +H /X /L ( 㻯㼡㼒㼒㻌㼜㼘㼍㼏㼑

36. Slide 36: Technical Expertise: Example Sskt

    㼀㼑㼏㼔㼚㼕㼏㼍㼘㻌㻱㼤㼜㼑㼞㼠㼕㼟㼑 ౛㻦㻌㻿㼗㼠 㻔㻿㼑㼙㼎㼍 㼑㼠㻌㼍㼘㻚㻌㻳㼑㼚㼑㼠㼕㼏㼟㻌㻝㻣㻞㻦㻠㻠㻡㻙 㼑㼠㻌㼍㼘㻚㻌㻳㼑㼚㼑㼠㼕㼏㼟㻌㻝㻣㻞㻦㻠㻠㻡㻙㻠㻡㻢㻘㻌㻞㻜㻜㻢㻕 $7* 7$$ *W*W *W*W *W *W 䝜䝄䞁䝤䝻䝑䝖 +HDUW %UDLQ ⬨⣴࡜᳝㛫ᯈ࡛ࡢⓎ⌧ ᳝㛫ᯈࡢ␗ᖖ 㻿㼗㼠 &RS\ULJKW‹ 7UDQV*HQLF,QF$OO5LJKWV5HVHUYHG

37. Slide 37: Technical Expertise: Example Crebbp

    㼀㼑㼏㼔㼚㼕㼏㼍㼘㻌㻱㼤㼜㼑㼞㼠㼕㼟㼑 ౛㻦㻌㻯㼞㼑㼎㼎㼜 㻔㻻㼕㼗㼑㻌㼑㼠㻌㼍㼘㻚㻌㻴㼡㼙㼍㼚㻌㻹㼛㼘㻚㻌㻳㼑㼚㼑㼠㻚㻌㻤㻦㻌㻟㻤㻣㻙 㻻㼕㼗㼑㻌㼑㼠㻌㼍㼘㻚㻌㻴㼡㼙㼍㼚㻌㻹㼛㼘㻚㻌㻳㼑㼚㼑㼠㻚㻌㻤㻦㻌㻟㻤㻣㻙㻟㻥㻢㻘㻌㻝㻥㻥㻥㻕 㻝 㻞 㻟 㻠 㻡 㻢㻙㻝㻝 㻝㻞㻙㻝㻢 㻝㻣㻙㻝㻥 㻞㻜 㻞㻝 㻞㻥㻘㻟㻜 㻟㻝 㻝㻡㻘㻝㻢 㻞㻞㻙㻞㻤 573&5DQDO\VLV 㻗㻛㻗 㻗㻛㻳㼠 㻳㼠㻛㻳㼠 㻯㻮㻼 㻯㻮㻼㻛E㻙㼓㼑㼛㻌㼒㼡㼟㼕㼛㼚 㛗ᮇグ᠈㞀ᐖ )HDUFRQGLWLRQLQJWHVW 㻝㻜㻜 㻥㻜 㻞㻠㻌㼔㼞 㻤㻜 㼠㼛㼚㼑 㻣㻜 㻢㻜 㻡㻜 㻝 㻞 㻟 㻠㻜 㻟㻜 㻼㼞㼑㻙 㻼㼞㼑㻙

38. Slide 38: Research Topics: New Functions of AIM (Cd5l)

    䊤㻚◊✲䝖䝢䝑䜽䝇 㻭㻵㻹㻌㻔㻯㼐㻡㼘㻕䛾᪂䛯䛺ᶵ⬟䠖⮬ᕫච␿䛸㛵㐃 $UDLHWDO&HOO5HSRUWV 㻯㼐㻡㼘㻦㻌㻯㼐㻡㻌㼍㼚㼠㼕㼓㼑㼚㻙㼘㼕㼗㼑 &RS\ULJKW‹ 7UDQV*HQLF,QF$OO5LJKWV5HVHUYHG

39. Slide 39: In Blood, AIM Binds to IgM

    ⾑ᾮ୰䠖$,0䛿,J0䛸⤖ྜ ⾑Ύ䛾䜴䜶䝇䝍䞁䝤䝻䝑䝖 DQWL$,0 DQWL,J0 $,0 $,0 U$,0 $,0 $,0 U$,0 N'D ,J0䛸⤖ྜ䛧䛯$,0 ! $,0 ⾑୰䛾$,0䛾䝃䜲䝈䛿ண᝿䜘䜚኱䛝䛔 䛭䛾䝃䜲䝈䛿䚸,J0䛸୍⮴ ⾑Ύ䛾䝃䜲䝈䛻䜘䜛ศ⏬ (OXWLRQFXUYH DQWL$,0 DQWL,J0 ,J0䛸$,0䛿ྠ䛨ศ⏬䛻Ꮡᅾ䛩䜛 &RS\ULJKW‹ 7UDQV*HQLF,QF$OO5LJKWV5HVHUYHG

40. Slide 40: Role of IgM: Preventing AIM Excretion in Urine

    ,J0䛾ᙺ๭䠖$,0䛾ᒀ୰᤼ἥ䛾㜼Ṇ $,0 䜰䝭䝜㓟䠅ᢞ୚ᐇ㦂 㼞㻭㻵㻹 㻔㻝㻜㻜㻌P㼓㻛㼙㼛㼡㼟㼑㻕㻌ᢞ୚ VHFUHWHGW\SH ,J0 GHILFLHQWPLFH $,0䛿䛩䜏䜔䛛䛻ᒀ୰䜈᤼ἥ䛥䜜䜛 ,J0ᢞ୚ᐇ㦂 ⾑୰䛾$,0䛿ቑຍ䛩䜛 &RS\ULJKW‹ 7UDQV*HQLF,QF$OO5LJKWV5HVHUYHG

41. Slide 41: Localization of AIM and IgM: Dendritic Cells

    $,0䛸,J0䛾ᒁᅾ䠖⭁⮚䛾ᶞ≧⣽⬊ $,0䛸,J0䛾ᒁᅾ $,0,J0䛾ὀධᐇ㦂 㻭㻵㻹䛚䜘䜃㻵㼓㻹䛿䚸⭁⮚䛾⬇୰ᚰ䛾ℐ⬊ᛶ 㼞㻭㻵㻹䜢 㻵㼓㻹䛸䛸䜒䛻ὀධ䛧䛯䛸䛝䛻䛾䜏ℐ⬊ᛶᶞ ᶞ≧⣽⬊䛻⵳✚ ≧⣽⬊䛻᳨ฟ䛥䜜䜛䚹㼍㼏㼏㼡㼙㼡㼘㼍㼠㼕㼛㼚㻌㼕㼚㻌㻲㻰㻯㼟㻌㼣㼍㼟㻌 㼛㼚㼘㼥㻌㼛㼎㼟㼑㼞㼢㼑㼐㻌㼣㼔㼑㼚㻌䛣䛾䛣䛸䛿䚸㻭㻵㻹䛜㻵㼓㻹䛸⤖ྜ 䛧䛶䛔䜛䛣䛸䜢♧၀䚹 &RS\ULJKW‹ 7UDQV*HQLF,QF$OO5LJKWV5HVHUYHG

42. Slide 42: Role of AIM: IgM Internalization

    $,0䛾ᙺ๭䠖,J0䛾LQWHUQDOL]DWLRQ $,0䛸,J0䛾ᒁᅾ 㻭㻵㻹䛜䛒䜛䛸㻵㼓㻹䛿䚸᳨ฟ䛥䜜䛺䛔 㻭㻵㻹䛜䛒䜛䛸㻵㼓㻹䛿䚸᳨ฟ䛥䜜䜛 㻭㻵㻹㻔㻙㻕 㻭㻵㻹㻔㻗㻕 㻵㼓㻹䛿䚸㻲㼏㻾䜔㻯㻟䛸⤖ྜ 㻵㼓㻹䛿䚸㻲㼏㻾䛻䜘䜚⣽⬊ෆ 㻮⣽⬊䜢άᛶ໬ ᢠయ⏘⏕ᢚไ ᢠయ⏘⏕⣽⬊䛜㻵㼓㻳⏘⏕ &RS\ULJKW‹ 7UDQV*HQLF,QF$OO5LJKWV5HVHUYHG

43. Slide 43: IgM Increase on High-Fat Diet: TLR4

    㧗⬡⫫㣗᫬䛾,J0䛾ୖ᪼䠖7/5 +)'䛻䜘䜛,J0䛾ୖ᪼ ,J0䛾ୖ᪼7/5䛾㛵୚ 䕿 ⾑Ύ,J0 $,0 ⾑Ύ,J0 䕔 $,0 Z Z Z 㧗⬡⫫㣗 㧗⬡⫫㣗 㻭㻵㻹Ḟᦆ䝬䜴䝇䛷䜒㻵㼓㻹䛿ୖ᪼ 㼀㻸㻾㻠Ḟᦆ䝬䜴䝇䛷䛿㻵㼓㻹䛾ୖ᪼䛺䛧 䖾ู䛾䝯䜹䝙䝈䝮䛻䜘䜛 䖾㼀㻸㻾㻠䛾䝅䜾䝘䝹䛜㻵㼓㻹䛾ቑຍ䛻㛵୚ &RS\ULJKW‹ 7UDQV*HQLF,QF$OO5LJKWV5HVHUYHG

44. Slide 44: Obesity and Autoimmunity

    ⫧‶䛸⮬ᕫච␿ ⢾ᒀ⑓䠖ᢠ䜲䞁䝇䝸䞁ᢠయ䚸ᢠJOXWDPLFDFLGGHFDUER[\ODVHᢠయ ៏ᛶ⏥≧⭢⅖䠖ᢠWK\URLGSHUR[LGDVHᢠయ䚸ᢠWK\URJOREXOLQᢠయ ୙ዷ䠖ᢠ⢭Ꮚᢠయ ⮬ᕫච␿䛾Ⓨ⏕䝯䜹䝙䝈䝮 ⫧‶ $,0䛾ୖ᪼ ,J 0⏘⏕ ℐ⬊ᛶᶞ≧⣽⬊䛷䛾 ,J0䛾㈓␃ %⣽⬊䛾่⃭ ,J*⮬ᕫᢠయ⏘⏕ &RS\ULJKW‹ 7UDQV*HQLF,QF$OO5LJKWV5HVHUYHG

45. Slide 45: Effect of AIM: Enhanced Autoantibody Production

    $,0䛾ᙳ㡪䠖⮬ᕫᢠయ⏘⏕ቑᙉ DXWRDQWLERG\WLWHU $,0 $,0 )ROGFKDQJHVLQ $,0Ḟᦆ䝬䜴䝇䛻䛚䛔䛶⮬ᕫᢠయ䛾⏘⏕䛜ᢚไ ⾑୰䛾$,0䛿䚸⫧‶㛵㐃⮬ᕫච␿⑌ᝈ䛾䝬䞊䜹䞊 &RS\ULJKW‹ 7UDQV*HQLF,QF$OO5LJKWV5HVHUYHG

46. Slide 46: KWWSZZZWUDQVJHQLFFRMS

    䡚ே䚻䛾೺ᗣ䛸㇏䛛䛺ᬽ䜙䛧䛾䛯䜑䛻䡚 KWWSZZZWUDQVJHQLFFRMS

Trans Genic Group — Q2 FY2014 Earnings Presentation on 6ix